Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Phase 3

Withdrawn

Conditions: Multiple Myeloma
Neoplasms
Plasma Cells
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Therapeutic Uses

Interventions: Drug: Lenalidomide

First Posted Date: 2014-06-04

Last Posted Date: 2018-04-10

Lead Sponsor: Celgene

Registration Number: NCT02155634

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly

Phase 4

Completed

Conditions: Squamous Cell Carcinoma
Adenocarcinoma
Carcinoma, Large Cell
Non-Small Cell Lung Cancer
Carcinoma
Lung Neoplasm

Interventions: Drug: nab-paclitaxel
Drug: Carboplatin

First Posted Date: 2014-05-30

Last Posted Date: 2018-09-24

Lead Sponsor: Celgene

Target Recruit Count: 143

Registration Number: NCT02151149

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Central Coast Medical Oncology Corporation, Santa Maria, California, United States
🇺🇸
Northshore University Healthsystem Research Institute, Evanston, Illinois, United States

and more 52 locations

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Vidaza®

First Posted Date: 2014-05-14

Last Posted Date: 2019-11-18

Lead Sponsor: Celgene

Target Recruit Count: 511

Registration Number: NCT02137629

Locations: 🇰🇷
Dongnam Inst. of Radiological & Medical Science, Busan, Korea, Republic of
🇰🇷
Dong-a University Medical Center, Busan, Korea, Republic of
🇰🇷
Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of

and more 44 locations

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Motolimod
Drug: Cetuximab
Drug: Nivolumab

First Posted Date: 2014-04-28

Last Posted Date: 2019-10-25

Lead Sponsor: Celgene

Target Recruit Count: 18

Registration Number: NCT02124850

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide

First Posted Date: 2014-04-11

Last Posted Date: 2021-04-14

Lead Sponsor: Celgene

Target Recruit Count: 46

Registration Number: NCT02112175

Locations: 🇫🇷
CHRU Hopital Claude Huriez, Lile Cedax, France
🇫🇷
Hopital Saint Louis, Paris, France
🇫🇷
CH Argenteuil Victor DupouyHematologie, Argenteuil, France

and more 70 locations

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-90001
Drug: Placebo

First Posted Date: 2014-04-10

Last Posted Date: 2014-10-15

Lead Sponsor: Celgene Corporation

Target Recruit Count: 96

Registration Number: NCT02110420

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: ABI-007

First Posted Date: 2014-04-03

Last Posted Date: 2020-04-21

Lead Sponsor: Celgene

Target Recruit Count: 41

Registration Number: NCT02103062

Locations: 🇫🇷
Centre Oscar Lambret, Dept. de Cancerologie Digestive et Urologique, Lille 59, France
🇫🇷
Institut Gustave Roussy Hematologie, Villejuif, France
🇫🇷
Institut Curie, Saint-Cloud, France

and more 3 locations

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma in Relapse
Refractory Multiple Myeloma
Multiple Myeloma

Interventions: Drug: pomalidomide
Drug: marizomib
Drug: low-dose dexamethasone

First Posted Date: 2014-04-03

Last Posted Date: 2017-11-22

Lead Sponsor: Celgene

Target Recruit Count: 38

Registration Number: NCT02103335

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States

and more 3 locations

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Phase 2

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: RPC4046
Drug: Placebo

First Posted Date: 2014-03-28

Last Posted Date: 2017-05-09

Lead Sponsor: Celgene

Target Recruit Count: 100

Registration Number: NCT02098473

Locations: 🇺🇸
West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States
🇺🇸
Metropolitan Gastroenterology Group Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
🇺🇸
GI Associates and Endoscopy Center-GI Clinical Research Department, Flowood, Mississippi, United States

and more 27 locations

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

Completed

Conditions: Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndrome

Interventions: Other: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion

First Posted Date: 2014-03-13

Last Posted Date: 2020-01-27

Lead Sponsor: Celgene

Target Recruit Count: 503

Registration Number: NCT02085798

Locations: 🇪🇸
Hospital Universitario Txagorritxu, Vitoria, Alava, Spain
🇪🇸
Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospital Punta de Europa, Algeciras, Cádiz, Spain

and more 47 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy